

Preferred Provider Network

- Feb 10, 2021



HONORHEALTH®

COLLABORATING FOR CARE


Innovation Care Partners & HonorHealth – Confidential Information

As of 02/10/2021

Agenda

- Overview of COVID-19 statistics
- Arizona progress with COVID-19
- Updates from CMS, and Community
- Updates from HonorHealth
- Guest speaker

John Hopkins Tracker




As of 2/8/2021

CORONAVIRUS STATUS 2/8/2021

- **World** 106.3 million cases, 2.3 million deaths
- **US** 27.0 million cases, 463K deaths
- **Arizona** 780 K cases, 14,048 deaths


7 Day Average for Maricopa County

1. Cases # -33.75% (417 per 100k)
2. Deaths # -15.65% (496)
3. % Positivity up # -3.15% (12.43)
4. Testing Vol # -12.75%
5. New COVID admits # -21.90%



As of 2/8/2021


ED Visits by Syndrome in United States




- **Coronavirus like illness (CLI) or a COVID-19 diagnostic code**
- **Influenza like illness (ILI without mention of specific influenza)**
- **Pneumonia**
- **Shortness of breath**

As of 2/8/21

US COVID-19 Cases Caused by Variants



Number of Cases



Filters

Variant B.1.1.7

Location	B.1.1.7 Variant
Florida	201
California	150
New York	59
Colorado	33
Michigan	29
Georgia	23
New Jersey	19

Territories AS GU MH FM MP PW PR VI



As of 2/8/21

INNOVATION
CARE PARTNERS
AFFILIATED WITH HONORHEALTH

HONORHEALTH®

<https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html>

Arizona State Report Profile – CDC, 1/31/21

	STATE	STATE, % CHANGE FROM PREVIOUS WEEK	FEMA/HHS REGION	UNITED STATES
NEW COVID-19 CASES (RATE PER 100,000)	40,219 (553)	-19%	192,941 (374)	1,075,727 (324)
VIRAL (RT-PCR) LAB TEST POSITIVITY RATE	15.8%	-2.2%*	11.1%	8.8%
TOTAL VIRAL (RT-PCR) LAB TESTS (TESTS PER 100,000)	239,119** (3,285**)	+6%**	1,451,515** (2,815**)	10,241,016** (3,085**)
COVID-19 DEATHS (RATE PER 100,000)	1,021 (14.0)	+6%	5,167 (10.0)	22,555 (6.8)


<https://beta.healthdata.gov/Community/COVID-19-State-Profile-Report-Arizona/iuqv-5x8z>

Arizona State Report Profile – CDC, 1/31/21

	STATE	STATE, % CHANGE FROM PREVIOUS WEEK	FEMA/HHS REGION	UNITED STATES
SNFs WITH ≥1 NEW RESIDENT COVID-19 CASE	38%†	-6%*	19%	23%
SNFs WITH ≥1 NEW STAFF COVID-19 CASE	50%†	-11%*	25%	37%
SNFs WITH ≥1 NEW RESIDENT COVID-19 DEATH	18%†	+3%*	11%	14%
CONFIRMED NEW COVID-19 HOSPITAL ADMISSIONS (RATE PER 100 BEDS)	3,158 (21)	-15% (-14%)	14,856 (17)	82,072 (11)
NUMBER OF HOSPITALS WITH SUPPLY SHORTAGES (PERCENT)	13 (15%)	+0%	95 (18%)	1,073 (21%)
NUMBER OF HOSPITALS WITH STAFF SHORTAGES (PERCENT)	26 (29%)	-10%	181 (34%)	877 (17%)

Arizona State Report Profile – CDC, 1/31/21


Hospitals Admissions, 89 hospitals reporting



Arizona State Report Profile – CDC, 1/31/21

As of 2/8/21

Hospitals Admissions, 89 hospitals reporting



COVID-19 Social Impact by CDC

15 EVENTS
Past 7 days

Map of news reports related to social impact events resulting from the COVID-19 outbreak in the United States, such as school closures, localized outbreaks, state of emergency declarations, etc.

DATE RANGE

Past 7 days

TYPE OF EVENT ?

Elder Care

Arizona surpasses 14K COVID-19 total deaths as hospital metrics continue gradual decline – The AZ Republic



Business Closure
Business Reopening
COVID-19 Case Clusters
Elder Care
Healthcare Facility
Healthcare Worker
Lockdown / Shelter in Place
Mass Testing
School Closure
State of Emergency Declaration



<https://covid.cdc.gov/covid-data-tracker/#social-impact>

Arizona Daily Case Counts


Select a county to filter the epi curve.



**January 4th
12,075**

Arizona COVID-19 Deaths

15.




Date 2/8/21

COVID-19 Deaths (total)

14,055

65+: 10,529





Recent deaths may not be reported yet. Cases missing the date of death are excluded from the graph above, but are included in all other numbers.

% Positive Diagnostic Tests increasing

As of 2/8/2021

tests/day



Less than 20 years	639,743
20 - 44 years	1,607,424
45 - 54 years	543,645
55 - 64 years	519,674
65 years and older	655,817
Unknown	9,597

■ People tested for COVID-19 and ■ percent positive by week



Percent positive is the number of people with a positive result in Electronic Laboratory Reporting (ELR), out of all people with COVID-19 testing reported via ELR in AZ. Diagnostic tests include PCR

Total % Positive COVID-19 Diagnostic Tests: **14.8%**

12%

Total % Positive COVID-19 Serology Tests: **10.4%**

44%



ICU Beds in Use in Arizona

As of 2/8/2021


Week of Jan 29, 2021

ICU Beds Occupied: 70%

ICU Beds Unoccupied: 2,261

COVID ICU Beds Occupied: 836

Non-COVID ICU Beds Occupied: 757



COVID-19 in the Long-Term Care Facilities

Of 7,395 COVID-19 cases among residents, **2,099 (28%)** have been hospitalized and **1,878 (25%)** have died.



Of 5,193 COVID-19 cases among staff, **222 (4%)** have been hospitalized and **13 (0%)** have died.

As of 2/8/2021

CMS COVID-19 Data Reporting for LTCF

As 2/8/21

Total Resident COVID-19 Cases and Deaths

TOTAL RESIDENT COVID-19 CONFIRMED CASES

611,805

TOTAL RESIDENT COVID-19 DEATHS

121,772

Total Staff COVID-19 Cases and Deaths


TOTAL STAFF COVID-19 CONFIRMED CASES

525,400

TOTAL STAFF COVID-19 DEATHS

1,499

Weekly Resident Cases and Deaths



IN THE NEWS

As of 02/10/2021

Travel Recommendations - CDC update Feb. 2nd



- ALL air passengers coming in to United States **require** to show a NEG COVID-19 test result or documentation of recovery from COVID-19 before they board a flight
- Obtain a viral test no more than 3 days before your return flight to the United States departs
- Make sure to get your test results (delay your travel if you are awaiting results)
- Keep a copy of your test results during travel.
- Take steps to reduce higher-risk activities for 14 days before your trip

Travel Recommendations - CDC update Feb. 2nd



- Get tested with a viral test 3-5 days **AFTER** travel **AND** stay home, self-quarantine for a full 7 days
 - Even if you test NEG, stay home and self-quarantine for the full 7 days.
 - If your test is positive, isolate yourself to protect others
- If you don't get tested, stay home and self-quarantine for 10 days after travel
- Avoid being around people who are at [increased risk for severe illness](#) for 14 days, whether you get tested or not


Travel Recommendations - CDC update Feb. 2nd



- Masks are required on planes, buses, trains, and other forms of public transportation traveling into, within, or out of the United States and in U.S. transportation hubs
- Travel increases your chance of getting and spreading COVID-19
- **No testing requirement for domestic travel** thus far, but may have to attest to being symptom-free

There is almost no flu season this year

Fig. 1: There is almost no flu season: % of Visits for Influenza-like Illness




Source: CDC

Key Points

- Flu activity is unusually low at this time but may increase in the coming months
- An annual flu vaccine is the best way to protect against flu and its potentially serious complications.

U.S. Hits Pandemic Milestone With More Vaccinated Than Cases




As of 2/8/2021

COVID-19 Vaccinations in the United States


As of 2/8/21



U.S. COVID-19 Vaccine Administration by Vaccine Type



Daily Count of Total Doses Administered and Reported to CDC



COVID-19 Vaccinations in the United States - LTCF

As of 2/8/21

Total Number of Doses Administered
in Long-Term Care Facilities

4,946,483

Number of People with 1 or More
Doses in Long-Term Care Facilities


3,778,298

Number of People with 2 Doses in
Long-Term Care
Facilities


1,146,775

CDC | Data as of: Feb 08 2021 6:00am ET | Posted: Feb 8 2021 12:26PM ET

Number of People with 1 or More Doses in
Long-Term Care Facilities




Number of People with 2 Doses
in Long-Term Care Facilities



COVID-19 Vaccinations in the United States - LTCF

Daily Count of Total Doses Administered and Reported to CDC




Arizona

Total LTC Doses Administered: 51,588

People in LTC with 1+ Doses: 46,405

People in LTC with 2 Doses: 5,024

Vaccine Hesitancy



Young adults ages 18-29, Black adults, Hispanic adults, those living in urban areas, one-third of Republicans and independents are the most likely to say they want to “wait and see” how the COVID-19 vaccine is working.

These populations are going to be key groups to reach in order to have successful vaccine uptake across the U.S. population.

Healthcare Workers

https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-monitor/?utm_source=web&utm_medium=trending&utm_campaign=COVID-19-vaccine-monitor

Will the vaccines protect against transmission?



- AstraZeneca released a report that finds a 67% reduction in virus detection
- Indicates vaccine not only protected against serious illness and death, but also has the potential to reduce transmission
- Suggest that a single dose of the vaccine is 76% effective in preventing SARS-CoV-2 infection

<https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval>

As of 2/8/2021

Mix- and – Match Vaccine Trial

- University of Oxford enrolling volunteers in an 820-person trial in UK
- Evaluate a combination of Pfizer (mRNA) for one dose and AstraZeneca (viral-vector) for the other dose
- AstraZeneca is testing with Sputnik V combination too
- May try different vaccine spacing
- Benefits – may train the immune system to recognize and attack a pathogen in different ways, potentially better efficacy



As of 2/8/2021

 INNOVATION
CARE PARTNERS
AFFILIATED WITH HONORHEALTH

HONORHEALTH®

Wall Street Journal, Feb 4 2021

Pfizer-BioNTech vaccine effective against UK variant

- Preprint study – “no biologically significant difference in neutralization activity” between B.1.1.7 and original strain
- All the mutations associated with new variant were neutralized by antibodies in the blood of 16 participants who had previously been given the vaccine
 - Half participants 18 to 55, the other half 56-85

MONOCLONAL ANTIBODY TREATMENTS

HonorHealth Monoclonal Antibody Process

Identify

- Provider identifies patient that meets criteria for monoclonal antibody treatment

Call

- Call COVID Infusion Line **480-587-7020** to refer patient
- Mon-Fri 8a-5p, 9a-1p weekends
- **Currently at Shea, Osborn, JCL, Sonoran Crossing**

Referral

- Nurse to review patient criteria, if meets criteria then patient will be referred to the closest HH ED

Please make sure your patient meets criteria BEFORE calling the COVID Infusion Line!

HonorHealth Monoclonal Ab Criteria

INCLUSION CRITERIA

- Age ≥ 18 years
- **First** COVID-19 positive test collected within 72 hours of monoclonal antibody infusion
- Mild to Moderate COVID-19 disease with one or more of the following symptoms within 10 days of symptom onset:
 - Fever ($t_{max} > 101.4$), cough, sore throat, malaise, headache, muscle pain, shortness of breath, GI symptoms
- **At risk for severe illness (must meet 1 or more of the following criteria):**
 - Age ≥ 65
 - Underlying medical condition
 - Obesity ($BMI \geq 35$)
 - Diabetes
 - Immunocompromised state and/or receiving immunosuppressive treatment
 - Chronic kidney disease
 - Age ≥ 55 and have one or more of the following
 - Cardiovascular disease, or hypertension, or COPD/other chronic respiratory disease

EXCLUSION CRITERIA

- Any hospitalized patient
- Requiring supplemental oxygen secondary to COVID-19 or require an increase in baseline oxygen flow rate due to COVID-19.
- Hemodynamic instability
- Suspected or proven serious bacterial, fungal, viral, or other infection
- History of previous positive SARS-CoV-2 serology test
- Any co-morbidity requiring surgery within < 7 days or considered life-threatening within 30 days
- Pregnant or breastfeeding women
- Pediatric
 - Age < 18 years

AZ COVID-19 Hotline for monoclonal Ab

For patients who meet criteria, providers can contact the COVID-19 Hotline (administered by Arizona Poison and Drug Information Systems) to determine the closest healthcare facility location that has received an allocation of Bamlanivimab and Casirivimab/Imdevimab (Regeneron):

844-542-8201


- Same criteria as HH except they **allow age 12-17 years** AND have one or more of the following:
 - BMI >85th percentile for age and gender
 - Sickle cell disease
 - Congenital or acquired heart disease
 - Neurodevelopmental disorders; for example, cerebral palsy
 - A medical-related technological dependence; for example, tracheostomy, gastrostomy, vent
 - Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control

VACCINE UPDATES



As of 02/10/2021

Vaccines Administered



Arizona


13.11
doses per 100 people

10.3%
of population got at least 1
shot

2.6%
Are fully vaccinated


35, 947 doses per day
9 months to cover 75% of
population

As of 2/9/2021




Vaccination Efforts

- In U.S., the latest vaccination rate is **1,470,823 doses** per day, on average.
- At this rate, it will take an **estimated 10 months** to cover **75%** of the population with a two-dose vaccine.




How State Vaccinations Stack Up
Alaska 20.9 vs Az 11.8 /100 doses

As of 2/9/2021



<https://ourworldindata.org/covid-vaccinations>

Worldwide Vaccine Status



67 vaccine candidates in clinical trials,
20 in the final stages of clinical testing
Janssen (Johnson & Johnson)
awaiting FDA approval

- Pfizer/BioNtech
- Moderna
- Sputnik V - Russia
- Oxford/AstraZeneca – UK
- CanSinoBIO - China
- BEKTOP - Russia
- BBIBP-CorV - China
- Sinovac - China
- Sinopharm - China
- Covaxin - India

As of 2/8/2021

Vaccine Grace Period

- Pfizer-BioNTech (30 µg, 0.3 ml each): 3 weeks (21 days) apart
 - ages ≥16 years
- Moderna (100 µg, 0.5 ml): 1 month (28 days) apart
 - ages ≥18 years
- BUT per CDC:
 - 2nd dose can be administered within a grace period of 4 days earlier than the recommended date AND
 - Administration up to 6 weeks (42 days) after the first dose
 - CDC is **not** advocating for people to delay getting their second dose, but the data from clinical trials support this range.

As of 2/9/2021

Vaccine Side Effects – mirror clinical trials

Local and systemic reactions, day 0-7*,†	All vaccines %	Pfizer- BioNTech dose 1 %	Pfizer-BioNtech dose 2 %	Moderna dose 1 %
Pain	70.7	67.7	74.8	70.1
Fatigue	33.4	28.6	50.0	29.7
Headache	29.4	25.6	41.9	26.0
Myalgia	22.8	17.2	41.6	19.6
Chills	11.5	7.0	26.7	9.3
Fever	11.4	7.4	25.2	9.1
Swelling	11.0	6.8	26.7	13.4
Joint pain	10.4	7.1	21.2	8.6
Nausea	8.9	7.0	13.9	7.7

As of 2/8/2021

Estimated anaphylaxis reporting rates following COVID-19 vaccines based on VAERS reports and reported doses administered

Reported vaccine doses administered	Anaphylaxis cases	Reporting rate (analytic period Dec 14-Jan 18)
Pfizer-BioNTech: 9,943,247	50	5.0 per million doses admin.
Moderna: 7,581,429	21	2.8 per million doses admin.

- Total COVID-19 vaccine doses administered thru Jan 18 by sex: Female 61%, Male 36%, Unk 3%
- Previously reported rate for Pfizer-BioNTech vaccine: 11.1 per million doses admin (Dec 14-Dec 23)
<https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm>
- Previously reported rate for Moderna vaccine: 2.5 per million doses admin (Dec 21-Jan 10)
<https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm>

	MAY PROCEED WITH VACCINATION	PRECAUTION TO VACCINATION	CONTRAINDICATION TO VACCINATION
CONDITIONS	CONDITIONS <ul style="list-style-type: none"> Immunocompromising conditions Pregnancy Lactation ACTIONS <ul style="list-style-type: none"> Additional information provided* 15 minute observation period 	CONDITIONS <ul style="list-style-type: none"> Moderate/severe acute illness ACTIONS <ul style="list-style-type: none"> Risk assessment Potential deferral of vaccination 15-minute observation period if vaccinated 	CONDITIONS <ul style="list-style-type: none"> None ACTIONS <ul style="list-style-type: none"> N/A
ALLERGIES	ALLERGIES History of allergies that are unrelated to components of an mRNA COVID-19 vaccine*, other vaccines, injectable therapies, or polysorbate, such as: <ul style="list-style-type: none"> Allergy to oral medications (including the oral equivalent of an injectable medication) History of food, pet, insect, venom, environmental, latex, etc., allergies Family history of allergies ACTIONS <ul style="list-style-type: none"> 30-minute observation period: Persons with a history of anaphylaxis (due to any cause) 15-minute observation period: All other persons 	ALLERGIES <ul style="list-style-type: none"> History of any immediate allergic reaction* to vaccines or injectable therapies (except those related to component of mRNA COVID-19 vaccines* or polysorbate, as these are contraindicated) ACTIONS: <ul style="list-style-type: none"> Risk assessment Consider deferral of vaccination and/or referral to allergist-immunologist 30-minute observation period if vaccinated 	ALLERGIES History of the following are contraindications to receiving either of the mRNA COVID-19 vaccines*: <ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components Immediate allergic reaction* of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components* (including polyethylene glycol)†‡ Immediate allergic reaction of any severity to polysorbate*‡ ACTIONS <ul style="list-style-type: none"> Do not vaccinate‡ Consider referral to allergist-immunologist

Vaccination recs for those with immune compromised conditions or allergies

As of 2/8/2021

Who Should and Should Not be Vaccinated










- Acutely ill with COVID-19 or other illness should defer until better
- If under quarantine for exposure, defer until quarantine completed
- OK for pregnant and breastfeeding individuals; CDC, ACOG, SMFM
- History of previous infection DOES NOT preclude vaccination
- Wait 90 days after antibody therapy to be vaccinated, 14 days after other vaccines
- If severe allergic reaction to 1st dose – can be vaccinated, observe 30 minutes BUT should work with their HCP or allergy specialist

MCDPH Vaccine Side Effect Policy

- Individuals who are vaccinated against SARS-CoV-2 (the virus that causes COVID-19) and develop post-vaccine side effects consistent with COVID-19 vaccination can return to work without viral testing if:
 - They feel well enough and are willing to work
 - They are afebrile*
 - Their side effects are limited to those associated with COVID-19 vaccination and not COVID-19 disease (cough, shortness of breath, sore throat, or change in smell or taste)
- If an individual's COVID-19 vaccination side effects persist for more than 2 days from onset to resolution and exceed 72 hours from vaccination, they should be excluded from work and viral testing should be considered.
- *Individuals with fever measured as 38°C or 100.4°F or higher should be excluded from work and viral testing should be considered if the fever persists **for more than 2 days. NOTE: For severe healthcare worker shortages, CDC allows staff to continue working with fever as long as other COVID-19 symptoms are absent.**

Operation Warp Speed EUA Tracker

Fig. 2: Operation Warp Speed EUA Tracker

Developer	Vaccine Candidate	Pre-Clinical	Phase 1	Phase 2	Phase 3	EUA Approval	Phase 3 Trial Results	Doses	Storage Requirement
J&J	JNJ-78436735	P1 Data Readout - Jan 13'21 (Positive)			P3 Trial Start Sept 3'20	Expected Mid-Feb'21 Mid Feb	66% *Phase 3 trial results from across eight countries and 44k+ volunteers		Standard Cold Chain
Astra Zeneca/Oxford	AZD1222	P1 Data Readout - Dec 8'20 (Flagged)			P3 Trial Start Aug 31'20	Delayed to March/Apr'21 March/April		 	Standard Cold Chain
Novavax	NVX-CoV2373	P1 Data Readout - March'21			P3 Trial Start Dec 28'20	Expected Apr-May'21 April/May		 	Standard Cold Chain
Sanofi Pasteur/GSK	SARS-CoV-2 Vaccine			P1/2 Trial Start Sept 3'20	Delayed to end of '21	End '21		 	Standard Cold Chain
Merck	V591		P1 Trial Start Sept'20		Discontinued 1/25/2021			 	Ultra Cold Chain


Source: Nephron Research analysis of data from the World Health Organization, Regulatory Affairs Professionals Society, STAT News, and company releases.

Novavax

- Novavax reported its vaccine offered robust protection per an early analysis of 15,000-person trial in Britain
- Efficacy nearly 90%
- Small trial in South Africa of 4,400 – efficacy just under 50% thought due to the variant B.1.351

<https://www.nytimes.com/2021/01/28/health/covid-vaccine-novavax-south-africa.html>

Janssen (Johnson & Johnson) Vaccine



- Pending submission for FDA EUA
- Viral vector vaccine – Adenovirus 26
- Requires 1 dose
- Studied in individuals 18 years and older

Vaccine in LTCF – Great early results

- Center for Health Policy Evaluation in Long-Term Care evaluated vaccine efficacy SNFs
- 797 nursing homes, first vaccination from Dec. 18, 2020 to Dec 27, 2020
- Three weeks after vaccination new COVID-19:
- New resident cases declined by 48% vs 21% non- vaccinated nursing homes
- New staff cases declined by 33% vs 18% in non-vaccinated facilities.

<https://www.ahcancal.org/Data-and-Research/Center-for-HPE/Documents/CHPE-Report-Vaccine-Effectiveness-Feb2021.pdf>

States are taking back unused COVID Vaccines

- Dozens of states and cities are diverting doses from a federal program to vaccinate long-term care facilities after the program over-estimated how many shots it would need
- Per CDC, a combination of vaccine hesitancy, over-estimation of the number of doses needed for the campaign
- It's not clear exactly how many doses are being diverted from the program
 - Illinois, announced it was taking 97,000 doses out of the program.

<https://www.cnbc.com/2021/02/06/states-are-taking-back-unused-covid-vaccine-doses-from-nursing-homes-.html>

City of Phoenix COVID-19 Testing

- The city of Phoenix wants to better serve underserved communities, introducing a 2nd mobile [COVID-19](#) testing lab
- Free COVID-19 testing sites on select dates
 - No cost to community members with no insurance
- The Mobile Testing Van offers viral and antibody tests - **rapid results within 15 minutes**. Testing is limited. Appointments required
- **Stationary Testing Site** (Maryvale Park 4420 N. 51st Ave., Phoenix, AZ 85031)
 - No out-of-pocket-cost to anyone. PCR test with results within 24 hours
 - Appointments recommended at: <https://vincerecancer.com> (but walk-ups are accepted at **this** location)

<https://www.phoenix.gov/newsroom/em-and-hs/1399>

HONORHEALTH UPDATES

As of 02/10/2021

HonorHealth

- COVID-19 Census is Down.
 - Down 50% from Mid-January.
- Still not allowing any visitors.



GUEST SPEAKER

Guest Speaker

- Joseph Furtado w/ Thema Health Services.
- Director of Business Development.



Questions – Type in Q & A Section

Post-Acute Website: <https://innovationcarepartners.com/postacutecommunications>



- If you have further questions or issues you would like to discuss
- Please contact:
Francisco Gonzalez– Preferred
Network & Clinical Development
Supervisor
fgonzalez@icphealth.com